Sanofi-Aventis Sa (SNY) 41.57 $SNY
SmarTrend Watching for Potential Rebound in Shares of Sanofi-Aventis After 2.19% Loss
Comtex SmarTrend(R) - Tue Aug 02, 3:48PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $41.52 to a high of $41.89. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $41.62 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 41.57 (-0.92)
Sanofi-Aventis Falls 2.19% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 02, 3:46PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $41.52 to a high of $41.89. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $41.62 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 41.57 (-0.92)
Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 4:19PM CDT
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 49.72 (-0.68), INVA: 12.84 (-0.20), ANIP: 61.02 (-0.04), SNY: 41.57 (-0.92)
Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:58AM CDT
Regeneron Pharmaceuticals (REGN), which is set to release second-quarter 2016 results on Aug 4, had recorded an average negative earnings surprise of 0.06% last quarter.
CNAT: 2.33 (+0.04), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Sanofi Announces Q2 2016 Results
PR Newswire - Fri Jul 29, 7:00AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SNY: 41.57 (-0.92)
VIDEO: Sanofi - Q2 2016 Results Interview with CEO Olivier Brandicourt
PR Newswire Europe - Fri Jul 29, 12:47AM CDT
PARIS, July 29, 2016 /PRNewswire/ --
SNY: 41.57 (-0.92)
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
PR Newswire - Wed Jul 27, 7:12PM CDT
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes.
SAN: 3.95 (-0.16), SNY: 41.57 (-0.92)
Pfizer Publishes Final Data from Atopic Dermatitis Studies
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:10AM CDT
Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
GWPH: 94.07 (-2.04), PFE: 36.39 (-0.92), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Amgen's Repatha Gains FDA Approval for New Dosing Option
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:20AM CDT
Amgen's (AMGN) PCSK9 inhibitor Repatha becomes the first and the only one to gain FDA approval for a monthly single-dose administration.
INVA: 12.84 (-0.20), AMGN: 174.15 (-0.01), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 12.84 (-0.20), PFE: 36.39 (-0.92), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 63.58 (-0.50), PFE: 36.39 (-0.92), ABBV: 66.78 (-0.16), SNY: 41.57 (-0.92), CELG: 114.29 (-0.40)
New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire Europe - Thu Jun 23, 6:57AM CDT
LYON, France, June 23, 2016 /PRNewswire/ --
SNY: 41.57 (-0.92)
Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.26% Rise
Comtex SmarTrend(R) - Wed Jun 22, 11:58AM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.99 to a high of $40.61. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.94 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 41.57 (-0.92)
Watch for Sanofi-Aventis to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:56AM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.99 to a high of $40.61. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.94 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 41.57 (-0.92)
Merck's Biosimilar Version of Lantus Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:14PM CDT
Merck (MRK) announced encouraging data from two phase III studies on MK-1293 for the treatment of type I and type II diabetes.
MRK: 58.33 (-0.33), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14), SNY: 41.57 (-0.92)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 3.95 (-0.16), SNY: 41.57 (-0.92)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 63.58 (-0.50), SAN: 3.95 (-0.16), SNY: 41.57 (-0.92)
SmarTrend Watching for Potential Rebound in Shares of Sanofi-Aventis After 2.19% Loss
Comtex SmarTrend(R) - Tue Aug 02, 3:48PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $41.52 to a high of $41.89. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $41.62 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 41.57 (-0.92)
Sanofi-Aventis Falls 2.19% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 02, 3:46PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $41.52 to a high of $41.89. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $41.62 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 41.57 (-0.92)
Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 4:19PM CDT
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 49.72 (-0.68), INVA: 12.84 (-0.20), ANIP: 61.02 (-0.04), SNY: 41.57 (-0.92)
Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:58AM CDT
Regeneron Pharmaceuticals (REGN), which is set to release second-quarter 2016 results on Aug 4, had recorded an average negative earnings surprise of 0.06% last quarter.
CNAT: 2.33 (+0.04), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Sanofi Announces Q2 2016 Results
PR Newswire - Fri Jul 29, 7:00AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SNY: 41.57 (-0.92)
VIDEO: Sanofi - Q2 2016 Results Interview with CEO Olivier Brandicourt
PR Newswire Europe - Fri Jul 29, 12:47AM CDT
PARIS, July 29, 2016 /PRNewswire/ --
SNY: 41.57 (-0.92)
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
PR Newswire - Wed Jul 27, 7:12PM CDT
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes.
SAN: 3.95 (-0.16), SNY: 41.57 (-0.92)
Pfizer Publishes Final Data from Atopic Dermatitis Studies
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:10AM CDT
Pfizer (PFE) announced findings from two pivotal phase III studies on crisaborole for the treatment of patients with mild-to-moderate atopic dermatitis.
GWPH: 94.07 (-2.04), PFE: 36.39 (-0.92), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Amgen's Repatha Gains FDA Approval for New Dosing Option
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:20AM CDT
Amgen's (AMGN) PCSK9 inhibitor Repatha becomes the first and the only one to gain FDA approval for a monthly single-dose administration.
INVA: 12.84 (-0.20), AMGN: 174.15 (-0.01), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 12.84 (-0.20), PFE: 36.39 (-0.92), SNY: 41.57 (-0.92), REGN: 434.90 (+0.90)
Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 63.58 (-0.50), PFE: 36.39 (-0.92), ABBV: 66.78 (-0.16), SNY: 41.57 (-0.92), CELG: 114.29 (-0.40)
New Four-Strain Influenza Vaccine, VaxigripTetra(TM), Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
PR Newswire Europe - Thu Jun 23, 6:57AM CDT
LYON, France, June 23, 2016 /PRNewswire/ --
SNY: 41.57 (-0.92)
Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.26% Rise
Comtex SmarTrend(R) - Wed Jun 22, 11:58AM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.99 to a high of $40.61. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.94 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 41.57 (-0.92)
Watch for Sanofi-Aventis to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:56AM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.99 to a high of $40.61. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.94 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 41.57 (-0.92)
Merck's Biosimilar Version of Lantus Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:14PM CDT
Merck (MRK) announced encouraging data from two phase III studies on MK-1293 for the treatment of type I and type II diabetes.
MRK: 58.33 (-0.33), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14), SNY: 41.57 (-0.92)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 3.95 (-0.16), SNY: 41.57 (-0.92)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 63.58 (-0.50), SAN: 3.95 (-0.16), SNY: 41.57 (-0.92)
